Long noncoding RNAs (lncRNAs) in pancreatic cancer progression

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / U-2602-2019en_US
dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorRabiee, Navid
dc.contributor.authorPrem Kumar, Alan
dc.contributor.authorSethi, Gautam
dc.contributor.authorZarrabi, Ali
dc.contributor.authorWang, Yuzhuo
dc.date.accessioned2022-05-23T08:33:15Z
dc.date.available2022-05-23T08:33:15Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractLong noncoding RNAs (lncRNAs) are RNA molecules involved in gene regulation at transcriptional, post-transcriptional, and epigenetic levels. lncRNAs participate in regulating apoptosis and autophagy in pancreatic cancer (PCa) and can promote and/or decrease the proliferation rate of tumor cells. The metastasis of PCa cells is tightly regulated by lncRNAs and they can affect the mechanism of epithelial-mesenchymal transition (EMT) to modulate metastasis. The drug resistance of PCa cells, especially to gemcitabine, can be affected by lncRNAs. In addition, lncRNAs enriched in exosomes can be transferred among tumor cells to regulate their proliferation and metastasis. Antitumor compounds, such as curcumin and ginsenosides, can regulate lncRNA expression in PCa therapy. As we discuss here, the expression level of lncRNAs can be considered as both a diagnostic and prognostic tool in patients with PCa. Teaser: We discuss the role of long noncoding RNAs in the proliferation, invasion, and therapy response of pancreatic cancer cells, evaluating their prognostic and diagnostic functions in the clinical course of this disease.en_US
dc.identifier.citationAshrafizadeh M, Rabiee N, Prem Kumar A, Sethi G, Zarrabi A, Wang Y. Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today. 2022 May 16:S1359-6446(22)00202-1. doi: 10.1016/j.drudis.2022.05.012. Epub ahead of print. PMID: 35589014.en_US
dc.identifier.doi10.1016/j.drudis.2022.05.012en_US
dc.identifier.issn1359-6446en_US
dc.identifier.pmid35589014en_US
dc.identifier.scopus2-s2.0-85130928828en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1016/j.drudis.2022.05.012
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2708
dc.identifier.wosWOS:000818687600014en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.ispartofDrug Discovery Todayen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCancer Therapyen_US
dc.subjectChemoresistanceen_US
dc.subjectInvasionen_US
dc.subjectIncRNAen_US
dc.subjectMiRNAen_US
dc.subjectPancreatic Canceren_US
dc.titleLong noncoding RNAs (lncRNAs) in pancreatic cancer progressionen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S1359644622002021-main.pdf
Boyut:
4.88 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu